Market revenue in 2022 | USD 370.0 million |
Market revenue in 2030 | USD 1,166.7 million |
Growth rate | 15.4% (CAGR from 2022 to 2030) |
Largest segment | Targeted sequencing and resequencing |
Fastest growing segment | Whole Genome Sequencing |
Historical data covered | 2018 - 2021 |
Base year for estimation | 2022 |
Forecast period covered | 2023 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Whole Genome Sequencing, Whole Exome Sequencing, Targeted Sequencing and Resequencing |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to clinical oncology next generation sequencing market will help companies and investors design strategic landscapes.
Targeted sequencing and resequencing was the largest segment with a revenue share of 72.73% in 2022. Horizon Databook has segmented the Global clinical oncology next generation sequencing market based on whole genome sequencing, whole exome sequencing, targeted sequencing and resequencing covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of global-level data and insights on the Global clinical oncology next generation sequencing market, including forecasts for subscribers. This global databook contains high-level insights into Global clinical oncology next generation sequencing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account